CPB Ljubljana 2018 course book

INDICATIONS OF COMBINED EBRT + BT

1. T1-2 tumors in patients ineligible for surgery with risk of lymph node involvement 2. Advanced T3-4 and/or N + tumors that would require surgery with functional or cosmetic impact (cheek, base of tongue) 3. Tumors for primary radiotherapy in whom a brachytherapy boost outweighs the discomfort of an interventional procedure (soft palate, tonsil, etc.).

- BT boost allows local dose escalation in PTV subvolumes. - Local control rates >80% are reported treated with 45-50 Gy of EBRT and 15-20 Gy of LDR BT (or PDR/HDR equivalent).